Premium
Follow‐up study of cardiac 123 I‐MIBG scintigraphy in idiopathic REM sleep behavior disorder
Author(s) -
Miyamoto T.,
Miyamoto M.,
Iwanami M.,
Hirata K.
Publication year - 2011
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/j.1468-1331.2011.03392.x
Subject(s) - medicine , rem sleep behavior disorder , rapid eye movement sleep , cardiology , parkinson's disease , scintigraphy , nuclear medicine , disease , psychiatry , electroencephalography
Background: Cardiac 123 I‐metaiodobenzylguanidine ( 123 I‐MIBG) uptake in patients with idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD) is markedly reduced, as in Parkinson’s disease (PD). Methods: We performed 123 I‐MIBG scintigrams on patients with iRBD and PD. After the initial 123 I‐MIBG scintigram, we retested subjects after a mean of 2.8 years. Results: The delayed heart‐to‐mediastinum (H/M) ratio of cardiac 123 I‐MIBG uptake was not significantly reduced between the first and second study in either group ( P = 0.050, P = 0.091, respectively) . Follow‐up imaging revealed a mean decline of 4.21 ± 9.06% or 6.40 ± 19.02% in the delayed H/M ratio in those with iRBD or PD, respectively. Conclusions: The 123 I‐MIBG uptake findings might indicate progression early in the course of iRBD or PD, but the progression is heterogeneous and independent of development of motor symptoms.